N-[(1S)-1-cyano-3-phenylpropyl]-4-phenylbutanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-[(1S)-1-cyano-3-phenylpropyl]-4-phenylbutanamide
• 化学式: C₂₀H₂₂N₂O
• 分子量: 306.4
• InChiKey: JWEIPHMUKZSLTR-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Novel compounds and compositions as cathepsin inhibitors
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US20040142999A1

  公开（公告）日：2004-07-22

  The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新型选择性卡硫化酶S抑制剂，其药学上可接受的盐和N-氧化物，其作为治疗剂的用途以及其制备方法。
• CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1397340A2

  公开（公告）日：2004-03-17
• USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1694357A1

  公开（公告）日：2006-08-30
• [EN] NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES EN TANT QU'INHIBITEURS DE CATHEPSINE
  申请人：AXYS PHARM INC

  公开号：WO2002098850A2

  公开（公告）日：2002-12-12

  The present invention relates to coumponds of formula (I) (in which X1 is-NHC(R1)(R2)X3 or -NHX4 and the other variables are as defined in the claims) and the pharmaceutically acceptable salts and N-oxides therof, useful as selective cathepsin S inhibitors, their uses as therapeutic agents and the methods for their making. Formula (I):
• [EN] USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC<br/>[FR] UTILISATION D'INHIBITEURS DE LA CATHEPSINE S POUR LE TRAITEMENT D'UNE REPONSE IMMUNE CAUSEE PAR ADMINISTRATION D'UNE PETITE MOLECULE THERAPEUTIQUE OU BIOLOGIQUE
  申请人：AXYS PHARM INC

  公开号：WO2005058348A1

  公开（公告）日：2005-06-30

  The present invention is directed to the use of Cathepsin S inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.